Du är här


Galapagos NV: Galapagos raises €2.4 million through warrant exercises

Mechelen, Belgium; 10 April 2014 - Galapagos NV (Euronext: GLPG) announced
today a share capital increase arising from warrant exercises.

Since its inception in 1999, Galapagos has used warrant plans to incentivize
personnel and management and have them share in the success of the company.
Following warrant exercises during the exercise period from 21 March 2014
through 3 April 2014, Galapagos issued 304,791 new ordinary shares for a
total capital increase (including issuance premium) of €2,381,210.31.

CEO Onno van de Stolpe exercised 30,000 warrants through a cashless exercise
facility. These warrants were due to expire on 1 June 2014. Onno van de
Stolpe holds an aggregate of 357,358 shares in Galapagos, representing 1.2%
of the outstanding Galapagos shares.

Other members of the Executive Committee exercised an aggregate amount of
82,500 warrants. Most of the warrants exercised by the other Executive
Committee members were due to expire on 1 June 2014. The remaining warrants
that were exercised by these members of the Executive Committee were
exercised under the Galapagos' Executive Committee warrant exercise program
whereby members have made a commitment to exercise a minimum number of
warrants during subsequent exercise periods, subject to certain conditions.
Other members of the Board of Directors exercised an aggregate of 12,540
warrants, all of which were due to expire on 1 June 2014.

To date, Galapagos' total share capital amounts to €162,820,555.17; the total
number of securities conferring voting rights is 30,098,837, which is also
the total number of voting rights (the "denominator"), and all securities
conferring voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued securities
conferring voting rights is 3,093,485, which equals the total number of
voting rights that may result from the exercise of these warrants. Galapagos
does not have any convertible bonds or shares without voting rights

About Galapagos
Galapagos(Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline comprising five Phase 2 studies (two led by GSK), one
Phase 1 study, six pre-clinical, and 20 discovery small-molecule and antibody
programs in cystic fibrosis, inflammation, antibiotics, metabolic disease,
and other indications. In the field of inflammation, AbbVie and Galapagos
signed a worldwide license agreement whereby AbbVie will be responsible for
further development and commercialization ofGLPG0634after Phase 2B. GLPG0634
is an orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases, currently
in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos has
another selective JAK1 inhibitor in Phase 2 in ulcerative colitis and
psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974is the first inhibitor of FFA2 to be evaluated clinically for
the treatment of IBD; this program is currently in a Proof-of-Concept Phase 2
study. GLPG1205is a first-in-class molecule that targets inflammatory
disorders and has completed Phase 1. AbbVie and Galapagos signed an
agreement in CF whereby they work collaboratively to develop and
commercialize oral drugs that address two mutations in the CFTR gene, the
G551D and F508del mutation. Potentiator GLPG1837 is at the pre-clinical
candidate stage. Galapagos has 400 employees, operating from its Mechelen,
Belgium headquarters and facilities in The Netherlands, France, and Croatia.
Further information at:www.glpg.com


Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications&Investor Relations
Tel: +31 6 2291 6240

This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.